Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Astrocytes appear to retaliate against AD

When brain cells start oozing too much of the amyloid protein that is the hallmark of Alzheimer's disease, the astrocytes that normally nourish and protect them deliver a suicide package instead, researchers report.

23 May 2012

Heart disease risk assessment tools often underestimate CVD danger faced by RA patients

Heart disease risk assessment tools commonly used by physicians often underestimate the cardiovascular disease danger faced by rheumatoid arthritis patients, a Mayo Clinic study has found. Inflammation plays a key role in putting those with rheumatoid arthritis in greater jeopardy for heart disease, yet many cardiovascular disease risk assessment methods do not factor it in, the researchers note.

22 May 2012

Study investigates link between BMI and cardiac function in obese adolescents

Obese adolescents with no symptoms of heart disease already have heart damage, according to new research.

21 May 2012

Nordic walking enables heart failure patients to exercise more intensely

Nordic walking enables heart failure patients to exercise more intensely than walking without poles.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Sleep-disordered breathing may increase risk of cancer mortality

Sleep-disordered breathing (SDB), commonly known as sleep apnea, is associated with an increased risk of cancer mortality, according to a new study.

21 May 2012

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH.

21 May 2012

LKCF, Spirit of Women’s HeartCaring to help reduce disparities in diagnosis and care

In an ongoing effort to save the lives of thousands of Americans at risk of cardiovascular ailments each year, Spirit of Women Health Network has joined forces with the Larry King Cardiac Foundation (LKCF) to help reduce the devastating disparity in the diagnostics, clinical care, and survival rate of heart attacks, strokes and other heart events for women and people of color.

19 May 2012

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

The Endocrine Society's new scientific statement published online today represents the first comprehensive evaluation of both the basic and clinical evidence related to the non-skeletal effects of vitamin D. The statement addresses current research regarding the associations of vitamin D with immune function, hypertension, stroke, skin conditions and maternal/fetal health.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

The truth about chocolate: does it really contain flavonoids?

There have been many news stories over the years about chocolate and whether it is good or bad for you. The stories often comment on a chemical constituent of chocolate: flavonoids. But what are flavonoids? Does chocolate even contain them? And why should we care if it does?

18 May 2012

Scientists investigate how ApoE4 gene contributes to Alzheimer's disease

A well-known genetic risk factor for Alzheimer's disease triggers a cascade of signaling that ultimately results in leaky blood vessels in the brain, allowing toxic substances to pour into brain tissue in large amounts, scientists report May 16 in the journal Nature.

17 May 2012

WHO releases World Health Statistics 2012 with first-time data on blood pressure, diabetes

The WHO on Wednesday released its World Health Statistics 2012 report, which "for the first time includes a look at blood pressure and glucose levels, two of the risk factors for diabetes and cardiovascular disease," according to the Associated Press/Washington Post.

17 May 2012

PPCI treatment on the rise among Stent for Life Initiative participants

Life saving primary percutaneous coronary intervention (PPCI) treatment is increasing in countries participating in the Stent for Life Initiative.

17 May 2012

CryoLife acquires Hemosphere

CryoLife, Inc., a leading medical device company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Hemosphere, Inc.

17 May 2012

World health statistics 2012 report puts spotlight on growing problem of NCD burden

The World health statistics 2012 report, released today, puts the spotlight on the growing problem of the noncommunicable diseases burden.

16 May 2012

Diabetes may affect 53.1M Americans by 2025: Study

The Diabetes 2025 Model for the U.S. projects a continuous and dramatic increase in the diabetes epidemic and makes it possible to estimate the potential effects of society-wide changes in lifestyle and healthcare delivery systems.

16 May 2012

Nile reports net operating loss of $0.8M for first quarter 2012

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012.

16 May 2012

Modest alcohol consumption linked with less evidence of steatohepatitis

NAFLD (non-alcoholic fatty liver disease) is the most common type of liver disease in the developed world, affecting up to one-third of the US population. NAFLD is often associated with obesity and other parameters of the so-called "metabolic syndrome," which is a major risk factor for the development of cardiovascular disease.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012